by Eric Christianson | Jan 14, 2024 | Cardiovascular Medication and Disease State Clinical Pearls
Fenofibrate is a lipid-lowering medication indicated as monotherapy to treat primary hyperlipidemia, mixed dyslipidemia, and hypertriglyceridemia. While this medication has been around for many years, its formulation has continued to evolve. The different fenofibrate...
by Eric Christianson | Jan 10, 2024 | Infectious Disease and Oncology Medication and Disease State Clinical Pearls
To be 100% transparent, I have never personally seen a case of tendon rupture that was likely due to quinolones. I have heard of one from another colleague. It is a very rare adverse effect that has been reported in numerous case studies. What I want you to be aware...
by Eric Christianson | Jan 7, 2024 | Infectious Disease and Oncology Medication and Disease State Clinical Pearls
As much as I would like to say I’ve never seen a patient have a pressure ulcer infection, I have. Pressure ulcer infections can be an issue in my geriatric population. There are numerous clinical pearls to remember in managing these types of infections. First...
by Eric Christianson | Dec 27, 2023 | Endocrine Medication and Disease State Clinical Pearls
We’ve taken the time to create a new free PDF resource. In my practice, I always run into nursing staff and caregivers who are using expired insulin or who are not dating the insulins that are in use. Insulin Storage and Beyond Use Dates Free PDF should be a...
by Eric Christianson | Dec 17, 2023 | Endocrine Medication and Disease State Clinical Pearls
Semaglutide products have been popping up in news headlines recently, and not because of their continued popularity as effective weight loss medications. Data from poison control centers across the country indicates a drastic increase over the past year in calls...
by Eric Christianson | Dec 13, 2023 | Psychiatry and Addiction Medication and Disease State Clinical Pearls
Alcohol use disorder can be managed with medications. American Psychiatric Association Guidelines recommend acamprosate or naltrexone as a first-line agent for moderate to severe management of alcohol use disorder. In this article, I will compare acamprosate versus...
